(Q62035362)
Statements
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis (English)
0 references
11 December 2018
0 references
3 December 2020
0 references
165
0 references
18 year
0 references
55 year
0 references